Page 102 - Read Online

Page 10 of 11 Sanal et al. Metab Target Organ Damage 2024;4:45 https://dx.doi.org/10.20517/mtod.2024.54

Nordisk, Astra Zeneca, Roche, BMS, Pfizer, Cincera, Pharmaxis, Gilead, AbbVie, and Boehringer Ingelheim.
Wei L consults for BI, Gilead, Hisky Medical, Kaiyin, MSD, Novo Nordisk, Pfizer, Roche, and VirsiRNA,
Speaker for Novo Nordisk and Sanofi, and receives research grants from Amoytop, AZ, Gilead, Kaiyin,
Pfizer, and Sanofi. The other authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2024.

REFERENCES
1. Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new
fatty liver disease nomenclature. J Hepatol 2023;79:1542-56. DOI PubMed
2. Angeli P. Democracy in science. J Hepatol 2024;80:676-7. DOI PubMed
3. Sanal MG. Biomarkers in nonalcoholic fatty liver disease-the emperor has no clothes? World J Gastroenterol 2015;21:3223-31. DOI
PubMed PMC
4. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med
2000;132:112-7. DOI PubMed
5. Meijnikman AS, Davids M, Herrema H, et al. Microbiome-derived ethanol in nonalcoholic fatty liver disease. Nat Med 2022;28:2100-
6. DOI PubMed
6. Sanal MG. The blind men ‘see’ the elephant-the many faces of fatty liver disease. World J Gastroenterol 2008;14:831-44. DOI
PubMed PMC
7. Kagansky N, Levy S, Keter D, et al. Non-alcoholic fatty liver disease - a common and benign finding in octogenarian patients. Liver
Int 2004;24:588-94. DOI PubMed
8. Solon-Biet SM, McMahon AC, Ballard JW, et al. The ratio of macronutrients, not caloric intake, dictates cardiometabolic health,
aging, and longevity in ad libitum-fed mice. Cell Metab 2014;19:418-30. DOI PubMed PMC
9. Odlyzko A. Newton’s financial misadventures in the South Sea Bubble. Notes Rec 2019;73:29-59. DOI
10. The Hill. Statue of revolutionary war general comes down in albany because he enslaved people. Available from: https://thehill.com/
homenews/4067139-statue-of-revolutionary-war-general-comes-down-in-albany-because-he-enslaved-people/. [Last accessed on 23
Nov 2024].
11. Alryalat SA, Rawashdeh K, El khatib O, et al. The change from an eponym to a representative name: wegener to granulomatosis with
polyangiitis. Sci Metri 2018;117:2077-89. DOI
12. Whitworth J, Woywodt A. Should eponyms be abandoned? BMJ 2007;335:0710346. DOI
13. Ducati RG, Ruffino-Netto A, Basso LA, Santos DS. The resumption of consumption - a review on tuberculosis. Mem Inst Oswaldo
Cruz 2006;101:697-714. DOI PubMed
14. Mohan V, Seedat YK, Pradeepa R. The rising burden of diabetes and hypertension in southeast asian and african regions: need for
effective strategies for prevention and control in primary health care settings. Int J Hypertens 2013;2013:409083. DOI PubMed PMC
15. Sanal MG. Is the change from NAFLD to MASLD driven by political correctness? J Hepatol 2024;80:e74-6. DOI PubMed
16. Fouad Y, Ghazinyan H, Alboraie M, et al. Joint position statement from the Middle East and North Africa and sub-Saharan Africa on
continuing to endorse the MAFLD definition. J Hepatol 2024;80:e194-7. DOI PubMed
17. Miao L, Ye S, Zheng MH; Global Chinese Fatty Liver Collaborative, Global Obesity Collaborative. “Fatty” or “steatotic”: position
statement from a linguistic perspective by the Chinese-speaking community. J Hepatol 2024;Online ahead of print. DOI PubMed
18. Wu T, Ye J, Mo S, et al. Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence
and screening: a prospective population survey in Asians. J Gastroenterol Hepatol 2024;39:1636-47. DOI PubMed
19. Ramírez-Mejía MM, Jiménez-Gutiérrez C, Eslam M, George J, Méndez-Sánchez N. Breaking new ground: MASLD vs. MAFLD-
which holds the key for risk stratification? Hepatol Int 2024;18:168-78. DOI PubMed
20. Huang CF, Yeh ML, Dai CY, Huang JF, Chuang WL, Yu ML. Chronic hepatitis C related steatotic liver disease is more than
“miscellaneous steatotic liver disease”. Clin Gastroenterol Hepatol 2024;22:2137-39.e2. DOI PubMed
21. Sanal MG. Biomarkers in nonalcoholic fatty liver disease-the emperor has no clothes? World J Gastroenterol 2015;21:3223-31. DOI
PubMed PMC
22. Lee MH, Chen YT, Huang YH, et al. Chronic viral hepatitis B and C outweigh MASLD in the associated risk of cirrhosis and HCC.